ArticlePloS one2011
Cysteamine attenuates the decreases in TrkB protein levels and the anxiety/depression-like behaviors in mice induced by corticosterone treatment.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- The Intricate Relationship of Trk Receptors in Brain Diseases and Disorders.Molecular neurobiology · 2025Review
- Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor.Frontiers in psychiatry · 2022Review
- Stress-Related Dysfunction of Adult Hippocampal Neurogenesis-An Attempt for Understanding Resilience?International journal of molecular sciences · 2021Review
- New agents and perspectives in the pharmacological treatment of major depressive disorder.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Morphological Responses of Excitatory Prelimbic and Orbitofrontal Cortical Neurons to Excess Corticosterone in Adolescence and Acute Stress in Adulthood.Frontiers in neuroanatomy · 2020Article
- Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases.Frontiers in neurology · 2019Review
- Prefrontal cortical trkB, glucocorticoids, and their interactions in stress and developmental contexts.Neuroscience and biobehavioral reviews · 2018Review
- Transglutaminase 2 Induces Deficits in Social Behavior in Mice.Neural plasticity · 2018Article
- Transglutaminase 2 overexpression induces depressive-like behavior and impaired TrkB signaling in mice.Molecular psychiatry · 2017Article
- Injection of Anti-proBDNF in Anterior Cingulate Cortex (ACC) Reverses Chronic Stress-Induced Adverse Mood Behaviors in Mice.Neurotoxicity research · 2017Article
- Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication.Brain, behavior, and immunity · 2016Article
- Angelica gigas ameliorate depression-like symptoms in rats following chronic corticosterone injection.BMC complementary and alternative medicine · 2015Article
- Cysteamine alleviates early brain injury via reducing oxidative stress and apoptosis in a rat experimental subarachnoid hemorrhage model.Cellular and molecular neurobiology · 2015Article
- A novel 2-decenoic acid thioester ameliorates corticosterone-induced depression- and anxiety-like behaviors and normalizes reduced hippocampal signal transduction in treated mice.Pharmacology research & perspectives · 2015Article
- Glucocorticoid regulates TrkB protein levels via c-Cbl dependent ubiquitination: a decrease in c-Cbl mRNA in the prefrontal cortex of suicide subjects.Psychoneuroendocrinology · 2014Article
- Research advances in treatment of neurological and psychological diseases by acupuncture at the Acupuncture Meridian Science Research Center.Integrative medicine research · 2014Review
- Foraging activity is reduced in a mouse model of depression.Neurotoxicity research · 2014Article
- Glucocorticoid regulates parkin expression in mouse frontal cortex: implications in schizophrenia.Current neuropharmacology · 2014Article
- Chronic administration of catechin decreases depression and anxiety-like behaviors in a rat model using chronic corticosterone injections.Biomolecules & therapeutics · 2013Article
- MicroRNA-132 may play a role in coexistence of depression and cardiovascular disease: a hypothesis.Medical science monitor : international medical journal of experimental and clinical research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have been shown to contribute significantly to the manifestation of anxiety-like behaviors observed in many neuropsychiatric disorders. Brain-derived neurotrophic factor (BDNF) signaling through its receptor TrkB plays an important role in stress-mediated changes in structural as well as functional neuroplasticity. Studies designed to elucidate the mechanisms whereby TrkB signaling is regulated in chronic stress might provide valuable information for the development of new therapeutic strategies for several stress-related psychiatric disorders. MATERIALS AND
methodsWe examined the potential of cysteamine, a neuroprotective compound to attenuate anxiety and depression like behaviors in a mouse model of anxiety/depression induced by chronic corticosterone exposure.
resultsCysteamine administration (150 mg/kg/day, through drinking water) for 21 days significantly ameliorated chronic corticosterone-induced decreases in TrkB protein levels in frontal cortex and hippocampus. Furthermore, cysteamine treatment reversed the anxiety and depression like behavioral abnormalities induced by chronic corticosterone treatment. Finally, mice deficient in TrkB, showed a reduced response to cysteamine in behavioral tests, suggesting that TrkB signaling plays an important role in the antidepressant effects of cysteamine.
conclusionsThe animal studies described here highlight the potential use of cysteamine as a novel therapeutic strategy for glucocorticoid-related symptoms of psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.